Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study

Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study

Introduction: This unplanned post-hoc analysis was based on data from the phase Ib DBL1002 study (NCT01569750) and evaluated the association between molecular biomarkers and clinical response to combined treatment with ibrutinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednis...

Full description

Bibliographic Details
Main Authors: Michael Schaffer, Shalini Chaturvedi, Cuc Davis, Jan de Jong, Regina Aquino, Yasuhiro Oki, Nele Fourneau, Anas Younes, Sriram Balasubramanian
Format: Article
Language:English
Published: Elsevier 2020-01-01
Series:Cancer Treatment and Research Communications
Subjects:
Biomarkers
Ibrutinib
R-chop
Diffuse large b-cell lymphoma
Phase Ib
Response to treatment
Online Access:http://www.sciencedirect.com/science/article/pii/S2468294220300708

Internet

http://www.sciencedirect.com/science/article/pii/S2468294220300708

Similar Items